Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation

Ann Hematol. 2017 Sep;96(9):1569-1572. doi: 10.1007/s00277-017-3033-7. Epub 2017 Jun 1.

Authors

Thomas S Y Chan¹, Joycelyn P Y Sim¹, Yok-Lam Kwong²

Affiliations

¹ Department of Medicine, Queen Mary Hospital, Pokfulam, Road, Hong Kong.
² Department of Medicine, Queen Mary Hospital, Pokfulam, Road, Hong Kong. ylkwong@hkucc.hku.hk.

PMID: 28573313
DOI: 10.1007/s00277-017-3033-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Allografts
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Combined Modality Therapy
Female
Hematopoietic Stem Cell Transplantation*
Humans
Neoplasm Proteins / antagonists & inhibitors
Neoplasm Proteins / immunology
Nivolumab
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Proof of Concept Study
Recurrence
Salvage Therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Neoplasm Proteins
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab